Background

Campath-1H is a potentially new treatment for Multiple Sclerosis or MS. The scientific name for Campath is alemtuzumab and the drug will in future be marketed as Lemtrada. It is awaiting approval for use in the treatment of MS. The drug is a monoclonal antibody designed to target that part of the immune system which is assumed to be harming people with MS (PwMS).  It has been developed for a number of years, and has already been used as a treatment for B-cell chronic lymphocytic leukaemia.

News

Phase III trials were completed by the end of 2012. The results of these trials and previous research can be found here.  Approval has now been sought from the FDA in America and the EMA in Europe. It is believed that decision on whether it can be prescribed will be issued in the second half of 2013

My diary has been updated as of July 2013. The gap between updates is simply due to the lack of any real news.

I have also updated the diary to reflect the name change of this drug to Lemtrada, so that future patients may still find this site.

Important

I am not a doctor, but a person with MS who has undergone this treatment. This site is no substitute for professional medical advice, but merely a tool for those seeking more information on this subject. Campath (or Lemtrada, alemtuzumab) is a powerful drug, and should only be considered as a treatment option after extensive consultations between a patient and their own medical practitioners.

Links are provided to sites outside this website. I am not responsible for the content on those external sites, nor do I endorse them. They are provided for information only.

Good luck in your fight with MS.

David Sturt  2003-2013